Study Results Find Interaction Between Fedratinib and a Strong Inhibitor of CYP3A4
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Diagnosis & Disease Information
Factors Underlying Ethnic Differences in Treatment Toxicity and Response in Advanced NSCLC: A Review
There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.
Should Age Be a Barrier to Clinical Trial Participation for Older Patients With Metastatic Renal Cell Carcinoma?
A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.
TKI Discontinuation for Patients With CML Could Save Billions
With the average uninsured cost of TKI treatment close to or above $146,000 per year per patient with CML in the United States, reducing or ending treatment would yield billions in savings.
TKI-treated Patients With CML May Have Increased Risk of Vascular Events
Patients with chronic myeloid leukemia (CML) treated with a first- or second-generation tyrosine kinase inhibitor (TKI) may have an increased risk of arterial and venous vascular events.
Cabozantinib Not Superior to Prednisone for Pretreated mCRPC
When compared to prednisone, cabozantinib failed to improve overall survival of heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).
Ponatinib Induces Durable Responses in Patients With CML for at Least 4 Years
Ponatinib resulted in durable responses after 4 years in heavily pretreated patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ribociclib Improves PFS in Treatment-naïve Patients With Advanced Breast Cancer
Adding ribociclib to letrozole significantly prolonged progression-free survival compared with letrozole alone in postmenopausal women.
Post-transplant Maintenance TKI Therapy Feasible for High-risk Ph+ Leukemia
Post-transplant maintenance TKI therapy is feasible and could be beneficial for patients with high-risk Philadelphia chromosome-positive leukemia.
Researchers Identify Risk Factors for Bosutinib-related Cardiac, Vascular Toxicities
Researchers sought to evaluate cardiac and vascular toxicities associated with long-term bosutinib treatment in patients with Ph-positive leukemia.
- Loading...
Loading...
Next post in Side Effect Management
Loading... 
Loading...